Table 1.
Characteristics of the study cohort (n = 20). Data are median (interquartile range) or n (%) values
| Age, years | 64.5 (58–70) |
| BMI, kg/m2 | 24 (22–27) |
| Never smoked | 10 (50) |
| Current or former smoker | 10 (50) |
| Diabetes mellitus | 4 (20) |
| Treated arterial hypertension | 6 (30) |
| Relevant cardiac medication | |
| ACEi/ARB | 6 (30) |
| Beta‐blocker | 7 (35) |
| Statin | 6 (30) |
| Aspirin | 6 (30) |
| Biochemistry | |
| Haemoglobin, g/dL | 13.5 (12.8–14.0) |
| Creatinine, μmol/L, | 58 (50–66) |
| HbA1c, % (n = 19) | 5.6 (5.2–5.7) |
| NT‐pro‐BNP, pmol/L (n = 19) | 235 (150–793) |
| Troponin T, ng/L (peak value) | 404 (163–682) |
| C‐reactive protein, mg/L (peak value) | 4.0 (1.3–21.5) |
| CK‐MB, μg/L (peak value) | 12 (5–22) |
| Coronary physiology | |
| Index of myocardial resistance | 16.5 (10.5–28.2) |
| Fractional flow reserve | 0.93 (0.88–0.96) |
| Coronary flow reserve | 2.4 (1.8–4.5) |
| Time from symptom onset to invasive coronary physiology examination, h | 40 (23–56) |
| Cardiac magnetic resonance imaging | |
| End diastolic volume, mL/m2 | 82 (74–91) |
| Stroke volume, mL/m2 | 32 (28–39) |
| Myocardial mass, g/m2 | 64 (56–70) |
| Ejection fraction (%) | 41 (31–48) |
| Affected region | |
| Apical | 13 (65) |
| Midventricular | 3 (15) |
| Multiple regions | 3 (15) |
| Regional | 1 (5) |
BMI, body mass index; ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; HbA1c, glycated haemoglobin; NT‐pro‐BNP, N‐terminal‐pro‐brain‐natriuretic peptide; CK‐MB, creatine kinase‐myocardial band.